2023 was a tough 12 months for the biopharma marketplace, with several organizations downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences sector from the latter Element of 2023 and possess ongoing their upswing https://sites.google.com/view/bio-sites/blog